细胞外囊泡DNA作为肿瘤液体活检分子的指标价值

doi:10.3760/cma.j.cn371439-20230523-00126

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (11): 668-671.doi: 10.3760/cma.j.cn371439-20230523-00126

细胞外囊泡DNA作为肿瘤液体活检分子的指标价值

尹树慧¹, 文荣², 苗淑芳¹()

¹内蒙古自治区国际蒙医医院临床检验中心，呼和浩特 010020
²包头医学院第一附属医院检验科，包头 014000

收稿日期:2023-05-23 修回日期:2023-07-05 出版日期:2023-11-08 发布日期:2024-01-11
通讯作者: 苗淑芳 E-mail:likingking1984@163.com
基金资助:
包头医学院科学研究基金(BYJJ-QM-201922)

Value of extracellular vesicle DNA as an indicator of tumor liquid biopsy molecules

Yin Shuhui¹, Wen Rong², Miao Shufang¹()

¹Center of Clinical Laboratory，Inner Mongolia International Mongolian Hospital，Hohhot 010020，China
²Depertment of Clinical Laboratory，First Affiliated Hospital of Baotou Medical College，Baotou 014000，China

Received:2023-05-23 Revised:2023-07-05 Online:2023-11-08 Published:2024-01-11
Contact: Miao Shufang E-mail:likingking1984@163.com
Supported by:
Scientific Research Fund of Baotou Medical College(BYJJ-QM-201922)

摘要/Abstract

摘要：

细胞外囊泡（EV）分布广泛，全面参与调控细胞生理的各项功能，作为分子生物标志物的活性载体和细胞间通讯的介质，参与肿瘤的发生、发展、转移、耐药等各个环节。EV可以从多种体液中获得，并且与组织具有高度同源性，在维持细胞稳态、细胞间物质交换和信息交流中起重要作用，已成为肿瘤诊断和治疗的理想生物标志物。在新兴的液体活检应用中，EV DNA可作为多种肿瘤的诊断和预后评估分子标志物，在肿瘤诊疗领域是极具潜力的液体活检分子指标。

关键词: 细胞外囊泡, 肿瘤, DNA

Abstract:

Extracellular vesicle （EV） is widely distributed and fully involved in the regulation of various aspects of cellular physiology. As active carriers of molecular biomarkers and mediators of intercellular communication，EV is involved in the occurrence，development，metastasis，drug resistance and other links of tumors. The EV，which can be obtained from a variety of body fluids and are highly homologous to tissues，plays an important role in the maintenance of cell homeostasis and the exchange of substances and information between cells，thus becoming an ideal biomarker for tumor diagnosis and treatment. In the emerging liquid biopsy application，EV DNA can be used as a molecular marker for the diagnosis and prognosis evaluation of many kinds of tumors，and it is the most potential molecular marker of liquid biopsy in the field of tumor diagnosis and treatment.

Key words: Extracellular vesicles, Neoplasms, DNA

尹树慧, 文荣, 苗淑芳. 细胞外囊泡DNA作为肿瘤液体活检分子的指标价值[J]. 国际肿瘤学杂志, 2023, 50(11): 668-671.

Yin Shuhui, Wen Rong, Miao Shufang. Value of extracellular vesicle DNA as an indicator of tumor liquid biopsy molecules[J]. Journal of International Oncology, 2023, 50(11): 668-671.

参考文献 27

[1]	Lee JS, Hur JY, Kim IA, et al. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA[J]. BMC Cancer, 2018, 18(1): 1236. DOI: 10.1186/s12885-018-5138-3. pmid: 30526536
[2]	Perdomo S, Avogbe PH, Foll M, et al. Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches[J]. Oncotarget, 2017, 8(42): 72621-72632. DOI: 10.18632/oncotarget.20004. pmid: 29069814
[3]	Ponti G, Manfredini M, Tomasi A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology[J]. Crit Rev Oncol Hematol, 2019, 141: 36-42. DOI: 10.1016/j.critrevonc.2019.06.005. pmid: 31212145
[4]	Russano M, Napolitano A, Ribelli G, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples[J]. J Exp Clin Cancer Res, 2020, 39(1): 95. DOI: 10.1186/s13046-020-01601-2. pmid: 32460897
[5]	Zhou B, Xu K, Zheng X, et al. Application of exosomes as liquid biopsy in clinical diagnosis[J]. Signal Transduct Target Ther, 2020, 5(1): 144. DOI: 10.1038/s41392-020-00258-9.
[6]	Valencia K, Montuenga LM. Exosomes in liquid biopsy: the nanometric world in the pursuit of precision oncology[J]. Cancers (Basel), 2021, 13(9): 2147. DOI: 10.3390/cancers13092147.
[7]	Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis[J]. Cells, 2019, 8(7): 727. DOI: 10.3390/cells8070727.
[8]	Whiteside TL. Tumor-derived exosomes and their role in cancer progression[J]. Adv Clin Chem, 2016, 74: 103-141. DOI: 10.1016/bs.acc.2015.12.005. pmid: 27117662
[9]	Amintas S, Vendrely V, Dupin C, et al. Next-generation cancer biomarkers: extracellular vesicle DNA as a circulating surrogate of tumor DNA[J]. Front Cell Dev Biol, 2021, 8: 622048. DOI: 10.3389/fcell.2020.622048.
[10]	Kim IA, Hur JY, Kim HJ, et al. Liquid biopsy using extracellular vesicle-derived DNA in lung adenocarcinoma[J]. J Pathol Transl Med, 2020, 54(6): 453-461. DOI: 10.4132/jptm.2020.08.13. pmid: 33027851
[11]	Akuma P, Okagu OD, Udenigwe CC. Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds[J]. Front Sustain Food Syst, 2019, 3: 23. DOI: 10.3389/fsufs.2019.00023.
[12]	Gorgannezhad L, Umer M, Islam MN, et al. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies[J]. Lab Chip, 2018, 18(8): 1174-1196. DOI: 10.1039/C8LC00100F. pmid: 29569666
[13]	Park J, Lee C, Eom JS, et al. Detection of EGFR mutations using bronchial washing-derived extracellular vesicles in patients with non-small-cell lung carcinoma[J]. Cancers (Basel), 2020, 12(10): 2822. DOI: 10.3390/cancers12102822.
[14]	Maire CL, Fuh MM, Kaulich K, et al. Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification[J]. Neuro Oncol, 2021, 23(7): 1087-1099. DOI: 10.1093/neuonc/noab012.
[15]	Qu X, Li Q, Yang J, et al. Double-stranded DNA in exosomes of malignant pleural effusions as a novel DNA source for EGFR mutation detection in lung adenocarcinoma[J]. Front Oncol, 2019, 9: 931. DOI: 10.3389/fonc.2019.00931. pmid: 31608233
[16]	Song Z, Cai Z, Yan J, et al. Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma[J]. Transl Lung Cancer Res, 2019, 8(4): 392-400. DOI: 10.21037/tlcr.2019.08.14.
[17]	Lee DH, Yoon H, Park S, et al. Urinary exosomal and cell-free DNA detects somatic mutation and copy number alteration in urothelial carcinoma of bladder[J]. Sci Rep, 2018, 8(1): 14707. DOI: 10.1038/s41598-018-32900-6. pmid: 30279572
[18]	Hur JY, Kim HJ, Lee JS, et al. Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients[J]. Mol Cancer, 2018, 17(1): 15. DOI: 10.1186/s12943-018-0772-6. pmid: 29374476
[19]	Rimmer MP, Gregory CD, Mitchell RT. Extracellular vesicles in urological malignancies[J]. Biochim Biophys Acta Rev Cancer, 2021, 8, 1876(1): 188570. DOI: 10.1016/j.bbcan.2021.188570.
[20]	Kitai Y, Kawasaki T, Sueyoshi T, et al. DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity[J]. J Immunol, 2017, 198(4): 1649-1659. DOI: 10.4049/jimmunol.1601694. pmid: 28069806
[21]	Torralba D, Baixauli F, Villarroya-Beltri C, et al. Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts[J]. Nat Commun, 2018, 9(1): 2658. DOI: 10.1038/s41467-018-05077-9. pmid: 29985392
[22]	Lian Q, Xu J, Yan S, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation[J]. Cell Res, 2017, 27(6): 784-800. DOI: 10.1038/cr.2017.54. pmid: 28409562
[23]	Rodríguez-Martínez A, de Miguel-Pérez D, Ortega FG, et al. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy[J]. Breast Cancer Res, 2019, 21(1): 21. DOI: 10.1186/s13058-019-1109-0. pmid: 30728048
[24]	Castellanos-Rizaldos E, Zhang X, Tadigotla VR, et al. Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients[J]. Oncotarget, 2019, 10(30): 2911-2920. DOI: 10.18632/oncotarget.26885. pmid: 31080561
[25]	Thakur K, Singh MS, Feldstein-Davydova S, et al. Extracellular vesicle-derived DNA vs. cfDNA as a biomarker for the detection of colon cancer[J]. Genes (Basel), 2021, 12(8): 1171. DOI: 10.3390/genes12081171.
[26]	Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients[J]. Ann Oncol, 2017, 28(4):741-747. DOI: 10.1093/annonc/mdx004. pmid: 28104621
[27]	Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer[J]. Gastroenterology, 2019, 156(1): 108-118.e4. DOI: 10.1053/j.gastro.2018.09.022. pmid: 30240661

细胞外囊泡DNA作为肿瘤液体活检分子的指标价值

Value of extracellular vesicle DNA as an indicator of tumor liquid biopsy molecules

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.